COMMUNIQUÉS West-GlobeNewswire

Ossur Hf : Transactions in relation to share buyback program

08/08/2017 - 18:00

A nnouncement from Össur hf. No. 55/2017 Reykjavík, 8 August 2017 On 1 December 2016, Össur hf. initiated a new share buy-back program, see Company announcement no. 96/2016. The purpose of the share buyback program is [...]

Novo Nordisk A/S - Share repurchase programme

08/08/2017 - 14:29

Bagsværd, Denmark, 8 August 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 [...]

iTeos Therapeutics SA: iTeos Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference

08/08/2017 - 14:00

iTeos Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference Gosselies, Belgium - August 8, 2017 - iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today [...]

FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares

08/08/2017 - 13:00

FIT Biotech Oy Company release August 8, 2017 at 02:00 PM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on September 26, 2016 [...]

uniQure Announces Second Quarter 2017 Financial Results and Recent Company Progress

08/08/2017 - 13:00

~ Advancing Gene Therapy Programs in Hemophilia B and Huntington's Disease ~ ~ Provides Update on Research Collaboration with Bristol-Myers Squibb ~ ~ Makes New Appointments to Company Leadership and Nominations to [...]

Verona Pharma plc Interim Results for the Six Months Ended June 30, 2017 and Clinical Development Update

08/08/2017 - 08:00

Completed US IPO Continues to advance lead candidate RPL554 with four clinical trials commenced LONDON, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a [...]

Communiqué de presse relatif à la solution ophtalmique de latanoprostène bunod, 0,024%

08/08/2017 - 07:30

Communiqué de presse Communiqué de presse relatif à la solution ophtalmique de latanoprostène bunod, 0,024% 8 août 2017 Sophia Antipolis, France Nicox S.A. (Euronext Paris : FR0013018124, COX, éligible PEA-PME), société [...]

Press Release concerning latanoprostene bunod ophthalmic solution, 0.024%

08/08/2017 - 07:30

Press Release Press Release concerning latanoprostene bunod ophthalmic solution, 0.024% 8 August 2017 Sophia Antipolis, France Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company [...]

argenx to Present at Wedbush PacGrow Healthcare Conference

08/08/2017 - 07:00

Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe [...]

MDxHealth Announces Service Agreement with Kaiser Southern California Permanente Medical Group

08/08/2017 - 07:00

COMPANY ANNOUNCEMENT / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, August 8, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced it has signed a health care services [...]

MDxHealth annonce un contrat de service avec Kaiser Southern California Permanente Medical Group

08/08/2017 - 07:00

Annonce d'entreprise / INFORMATION REGLEMENTAIRE / INFORMATION PRIVILEGIEE IRVINE, CALIFORNIE et HERSTAL, BELGIQUE - 07:00 CEST, le 8 août, 2017 - MDxHealth SA (Euronext: MDXH.BR) a annoncé aujourd'hui la signature d'un [...]

INNATE PHARMA : Nouveau nombre d'actions et de droits de vote d'Innate Pharma au 4 aout 2017

08/08/2017 - 07:00

nouveau NOMBRE D'ACTIONS ET DE DROITS DE VOTE d'InnatE Pharma AU 4 août 2017 Marseille, le 8 août 2017, 7h00 CEST Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l'Autorité [...]

INNATE PHARMA : Number of shares and voting rights of Innate Pharma as at August 4, 2017

08/08/2017 - 07:00

NUMBER OF SHARES AND VOTING RIGHTS OF Innate Pharma AS AT AUGUST 4, 2017 Marseille, France, AUGUST 8, 2017, 7:00 AM CEST Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of [...]

VIFOR PHARMA REPORTS STRONG H1 2017 RESULTS AND RAISES GUIDANCE

08/08/2017 - 06:55

PRESSEMITTEILUNG PRESS RELEASE COMMUNIQUÉ DE PRESSE This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that [...]

Sanofi : Disclosure of trading in own shares

07/08/2017 - 18:00

Reporting EN This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]

Sanofi : Déclaration des transactions sur actions propres

07/08/2017 - 18:00

Reporting FR This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]

Essilor : Nombre total de droits de vote et d'actions composant le capital social au 31 juillet 2017

07/08/2017 - 18:00

Nombre total de droits de vote et d'actions composant le capital social au 31 juillet 2017 (Article L.233-8 II du Code de Commerce et les articles 221-1 et 223-16 du Règlement Général de l'AMF) Charenton-le-Pont, France [...]

Essilor: Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2017

07/08/2017 - 18:00

Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2017 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]

Oriola Corporation - Repurchase of own shares on 7 August 2017

07/08/2017 - 17:45

ORIOLA CORPORATION STOCK EXCHANGE RELEASE 7 August 2017 AT 18:45 EEST In the Nasdaq Helsinki Date 7 August 2017 Exchange transaction Buy Share trading code OKDBV Amount, shares 16 584 Average price/share, EUR 3.6823 [...]